Reach

Diaceutics launches significant upgrade to its DXRX platform

New functionality will involve a best in class combination of generative AI and integrated data solutions to improve patient outcomes

Belfast and London, 21 March 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, has launched a significant upgrade to its DXRX platform, including industry and technologically leading de-identification, generative AI (Diaceutics Large Lab Model, DLLM) and new comprehensive US data sets that include data on social determinants of health. Not only does the upgrade increase the power and efficiency of the platform, but also the applicability of Diaceutics' subscription services into new parts of the precision medicine lifecycle, expanding the Company's addressable market.

This new functionality enables the DXRX platform to breakdown siloed datasets and provide greater depth and breadth of Diaceutics' longitudinal insight of the patient journey, at increased speed and scale. As a result of the upgrade, multiple stakeholders within the life sciences industry can now access a best in class, real world data set that is HIPAA compliant, at a pace that previously would not have been possible, helping to address healthcare inequalities and enable more patients to access appropriate therapies.

Jordan Clark, Chief Data Officer of Diaceutics commented: "Our Practise Gaps Study identified that a staggering 64.4% of patients do not get the right treatment. We seek to address that through the insights we provide, and today's platform upgrade will empower healthcare providers to make timely and accurate treatment decisions, ultimately benefiting more patients."

Enquiries: 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.